EMA agrees to review MMA of cannabidiol

Amy Schofield 07 February 2018

The European Medicines Agency (EMA) has accepted GW Pharmaceuticals' request to review the Marketing Authorisation Application (MAA) of Epidiolex, or cannibidiol.

The medication is used to treat patients who suffer from seizures linked to Lennox-Gastaut syndrome and Dravet syndrome.

The biopharmaceutical first submitted Epidiolex for review in December 2017. The successful filing of the MAA of the drug follows the application acceptance by the U.S. Food and Drug Administration from December, as well as the recent publication of Phase 3 LGS results in The Lancet.

The outcome of the MAA review by the EMA will be announced during the first quarter of 2019. GW Pharmaceuticals has been preparing itself for the commercialisation of Epidiolex in Europe by hiring staff in its medical affairs area, as well as market access and marketing, all of whom have experience with epilepsy or specialist disease.

CEO Justin Gover said: “We continue to build European commercial infrastructure in anticipation of future approval and launch with the goal of making this important new medicine available to appropriate patients and their caregivers, addressing the significant unmet need in LGS and Dravet syndrome, two rare and debilitating conditions of childhood-onset epilepsy."


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.